Table 2.
The disease-free survival events in the cohort study (n = 120).
| Variable | Trastuzumab-plus-chemotherapy group (n = 36) | Trastuzumab-monotherapy group (n = 52) | Non-trastuzumab group (n = 32) |
|---|---|---|---|
| Total events of diseasea | 0 | 4 | 7 |
| ipsilateral breast recurrence | 0 | 0 | 1 |
| regional lymph node | 0 | 0 | 2 |
| Distant | 0 | 4 | 5 |
| second malignancy | 1 | 2 | 0 |
| causes of death | 0 | 3 | 4 |
| breast cancer specific | 0 | 3 | 3 |
| Others | 0 | 0 | 1 |
a
Including all recurrences in the breast and regional lymph nodes, distant metastasis, second malignancies, and death. Duplications were observed.